Assessment of oral valaciclovir on inter appointment endodontic pain in single-rooted necrotic teeth with symptomatic apical periodontitis; A Randomized Placebo-controlled triple-blinded Clinical Trial

Assessment of oral valaciclovir compared to the control group on inter appointment endodontic pain in single-rooted necrotic teeth with symptomatic apical periodontitis; A Randomized Clinical Trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240906062957N1

Enrollment

Registered

2024-10-31

Start date

2024-10-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic apical periodontitis. Acute apical periodontitis of pulpal origin

Interventions

Intervention 1: After isolation with a rubber dam and determining the working length with an apex locator, the canal preparation is completed using Denco Blue files up to a size 2F. The canal is irrig

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Anterior and posterior single rooted teeth Necrotic teeth with symptomatic apical periodontitis

Exclusion criteria

Exclusion criteria: Teeth whose crowns cannot be restored. Presence of endo-perio lesion Teeth with complex anatomy (according to AAE Endodontic Case Difficulty Assessment Form• and Guidelines) Teeth with Internal and external resorption Calcified canals Teeth with occlusal interference Patients with parafunction Patients with systemic disease and migraine (patients who are in 2ASA and above) Patients with mental and intellectual problems Patients who use drugs that affect the perception of pain Cases where the cause of pain is more than two teeth Single-rooted two-canal teeth Pregnant and lactating patients Patients who are taking antibiotics or antivirals Endodontic lesion Dilaceration Patients with marginal periodontitis Patients with allergies to the drugs used in the study Patients with immune system deficiency

Design outcomes

Primary

Measure	Time frame
Pain level. Timepoint: 6, 24, 48 hours after first treatment session. Method of measurement: Visual Analogue Scale.;Number of painkillers taken. Timepoint: Within 48 hours after the first treatment session. Method of measurement: Count by patient.;Time. Timepoint: Elapsed time since the first treatment session. Method of measurement: Time 6, 24, 48 hours after the first treatment session.;Type of drug used. Timepoint: According to the prescribed instructions (one hour before starting the treatment 2 garms and 12 hours later again 2 grams and the next day twice a day 1 gram). Method of measurement: A or B based Random selection envelopes containing Placebo or drug.	—

Measure

Time frame

Pain level. Timepoint: 6, 24, 48 hours after first treatment session. Method of measurement: Visual Analogue Scale.;Number of painkillers taken. Timepoint: Within 48 hours after the first treatment session. Method of measurement: Count by patient.;Time. Timepoint: Elapsed time since the first treatment session. Method of measurement: Time 6, 24, 48 hours after the first treatment session.;Type of drug used. Timepoint: According to the prescribed instructions (one hour before starting the treatment 2 garms and 12 hours later again 2 grams and the next day twice a day 1 gram). Method of measurement: A or B based Random selection envelopes containing Placebo or drug.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedtaha Adnaninia

Tehran University of Medical Sciences

taha.adnani@gmail.com+98 21 2288 3469

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026